Affymetrix Partners With Fisher Scientific to Expand Markets for the World’s First Personal Microarray System
January 12 2011 - 6:00AM
Business Wire
Affymetrix, Inc. (NASDAQ:AFFX) today announced that it has
signed a distribution agreement with Fisher Scientific, Inc., part
of Thermo Fisher Scientific, to distribute the GeneAtlas™ System
and its related consumables through the Fisher Scientific channel
throughout the United States and Canada. The GeneAtlas System is
the first personal microarray solution to meet the demand among
life scientists for an easy to use and affordable way to
interrogate the whole genome. Fisher Scientific has a leading
position in the life sciences market and provides an unparalleled
reach and a proven record of customer service and support.
The GeneAtlas(tm) System brings the power
of Affymetrix microarrays to every researchers' lab and provides a
complete personal solution for processing Affymetrix microarrays.
(Photo: Business Wire)
“We are excited to reach this agreement with Fisher Scientific
because it allows us to expand our commercial sales in research
markets while maintaining our focus further downstream in
validation and clinical markets,” said Andy Last, Chief Commercial
Officer at Affymetrix. “Now we have a partner with the industry’s
strongest customer channel to take this technology to the broadest
life scientist community, which is key to the GeneAtlas System’s
success.”
The strategic partnership will bring the superior microarray
technology of Affymetrix to every lab, putting whole-genome
analysis into the hands of every researcher who has been limited by
budget and inhibited by the complexity of microarray systems. Life
scientists will no longer be forced to use less powerful
technologies; settling for a limited view of the genome will become
a thing of the past.
“We are also excited to be entering into this relationship with
Affymetrix; it broadens our extensive genomic research portfolio
and allows us to offer a full suite of solutions from discovery
research through to validation,” said Dan Pantano, President of
Fisher Scientific. “By partnering with the industry innovator and
pioneer in microarray technology it provides Fisher Scientific an
opportunity to offer customers a premium option when faced with
challenging genomic research, and the GeneAtlas System is the
perfect solution for many customers we routinely serve,” Pantano
added.
At a never-before-seen price for a complete microarray analysis
solution, the GeneAtlas System allows researchers to take control
of their samples and accelerate their pace to results and
publication. The easy-to-use bench top design provides a complete
end-to-end solution for processing the industry’s most widely cited
gene expression arrays and analyzing biological pathways. With
integrated data analysis designed for biologists, not
bioinformaticians, and wizard-driven statistical and pathway
analysis, life scientists are only nine clicks away from data to
pathways when using the GeneAtlas System, the simplest microarray
workflow available.
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading
academic, government, and nonprofit research institutes. More than
2,000 systems have been shipped around the world and more than
22,000 peer-reviewed papers have been published using the
technology.
Affymetrix is headquartered in Santa Clara, Calif., and has
manufacturing facilities in Santa Clara, Cleveland, Ohio, and
Singapore. The company has about 1,000 employees worldwide and
maintains sales and distribution operations across Europe and Asia.
For more information about Affymetrix, please visit
http://www.affymetrix.com.
Disclaimer
The information stated above was prepared by Affymetrix, Inc.
and reflects solely the opinion of Affymetrix, Inc. Nothing in this
statement shall be construed to imply any support or endorsement of
Affymetrix, Inc., or any of its products, by Fisher Scientific,
Inc., its officers, agents and employees.
Forward-looking statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix’ “expectations,” “beliefs,” “hopes,”
“intentions,” “strategies” or the like. Such statements are subject
to risks and uncertainties that could cause actual results to
differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix’ Form 10-K for the
year ended December 31, 2009, and other SEC reports for subsequent
quarterly periods.
NOTE: Affymetrix, the Affymetrix logo, and GeneAtlas System are
trademarks or registered trademarks of Affymetrix Inc.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6570378&lang=en
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2023 to Sep 2024